Summary
Used AI-driven computational models to simulate human diseases at tissue and cell resolution for drug development. Enabled in silico trials and mechanistic analysis to guide target selection and portfolio decisions. Helped pharmaceutical companies shorten clinical development cycles, reduce research costs, and improve the likelihood of successful approvals.